Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …

Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …

Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly
successful in decreasing disease severity; however, the recent emergence of the heavily …

Objective To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …

Coronavirus disease 2019 (COVID-19) is a viral infection with the novel severe acute
respiratory distress syndrome corona virus 2 (SARS-CoV-2). Until now, more than 670 …

Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces …

The world has faced 3 years of the COVID-19 pandemic with billions of infections, millions of
deaths, and a massive economic crisis. Since the pandemic began, scientists have started to …

Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …

Importance Several pharmacotherapies have been authorized to treat nonhospitalized
persons with symptomatic COVID-19. Longitudinal information on the use of these therapies …